11/11
10:10 am
cldx
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
Medium
Report
Celldex Therapeutics (NASDAQ:CLDX) had its price target lowered by analysts at Barclays PLC from $25.00 to $21.00. They now have an "underweight" rating on the stock.
11/10
04:01 pm
cldx
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/10
08:01 am
cldx
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Low
Report
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
11/7
08:01 am
cldx
Celldex to Present at Upcoming Investor Conferences
Low
Report
Celldex to Present at Upcoming Investor Conferences
11/6
08:00 am
cldx
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
Medium
Report
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
11/6
08:00 am
cldx
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients wi
Medium
Report
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients wi
10/30
04:01 pm
cldx
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
Low
Report
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
10/21
08:03 am
cldx
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $48.00 price target on the stock.
Low
Report
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Mizuho. They set an "outperform" rating and a $48.00 price target on the stock.
10/14
09:01 am
cldx
Verily Launches Landmark Partnership With CU Anschutz And UCHealth [Forbes]
Low
Report
Verily Launches Landmark Partnership With CU Anschutz And UCHealth [Forbes]
10/13
08:20 am
cldx
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $25.00 price target on the stock.
Low
Report
Celldex Therapeutics (NASDAQ:CLDX) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $25.00 price target on the stock.
9/17
09:40 am
cldx
Celldex Therapeutics (NASDAQ:CLDX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $62.00 price target on the stock.
Low
Report
Celldex Therapeutics (NASDAQ:CLDX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $62.00 price target on the stock.
9/17
05:11 am
cldx
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
Low
Report
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
9/9
09:01 am
cldx
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
Low
Report
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference